Nutriband shares surge 12.5% after-hours after agreeing to sell 90% of Pocono Pharma to EarthVision Bio for $5M, funding AVERSA Fentanyl development.

Nutriband Inc. surged 12.5% in after-hours trading following the announcement of a $5 million agreement to sell 90% of its subsidiary Pocono Pharmaceutical to EarthVision Bio, retaining a 10% stake in the acquiring company. The transaction, slated to close by December 31, 2025, positions proceeds toward advancing AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch with projected U.S. annual sales of $80 million–$200 million. The deal underscores strategic focus on high-potential pharmaceutical innovation while leveraging EarthVision Bio’s sustainable product development expertise led by Intel founder Dr. Gordon Moore and Chevron Europe’s former chairman Dr. Hans Franke. The retained equity stake and targeted reinvestment in a market-sensitive product likely drove investor optimism, aligning with the stock’s upward trajectory.